Background: Antiplatelet agents are the mainstay for secondary prevention of non-cardioembolic stroke. This systematic review examined the safety and efficacy of short-, middle-, and long-term aspirin in combination with clopidogrel as secondary prevention of stroke or transient ischemic attack (TIA) of presumed arterial origin. Methods: PubMed, EmBase, and CENTRAL were searched up to May 2014. Randomized controlled trials (RCTs) that compared aspirin plus clopidogrel versus aspirin or clopidogrel as secondary prevention of stroke or TIA of arterial origin were included. The analyses were stratified into short-term (≤3 months), middle-term (>3 months and <1 year), and long-term (≥1 year). Outcomes were compared using risk ratio (RR) and 95% confidence interval (95% CI). Results: Eight RCTs (20,728 patients) were included in the overall analysis. Compared with aspirin or clopidogrel alone, the complete analysis of all the data indicated that the combination therapy significantly reduced the risk of stroke recurrence (RR, 0.82; 95% CI 0.70-0.96, p = 0.01) and major vascular events (RR, 0.84; 95% CI 0.73-0.96, p < 0.01). But the risk of hemorrhagic stroke (RR, 1.59; 95% CI 1.08-2.33, p = 0.02) and major bleeding (RR, 1.83; 95% CI 1.37-2.45, p < 0.01) was increased. No RCT studied middle-term combination therapy. The analyses were therefore stratified into only two subgroups, short- and long-term treatment. Stratified analysis of short-term treatment showed that relative to monotherapy, the drug combination reduced the risk of stroke recurrence (RR, 0.69; 95% CI 0.59-0.81, p < 0.01) and did not increase the risk of hemorrhagic stroke (RR, 1.23; 95% CI 0.50-3.04, p = 0.65) and major bleeding events (RR, 2.17; 95% CI 0.18-25.71, p = 0.54). Short-term combination therapy was associated with a significantly lower risk of major vascular events (RR, 0.70; 95% CI 0.69 to 0.82, p < 0.01). Stratified analysis of long-term treatment revealed that the combination treatment did not decrease the risk of stroke recurrence (RR, 0.92; 95% CI 0.83-1.03, p = 0.15), but was associated with a significantly higher risk of hemorrhagic stroke (RR, 1.67; 95% CI 1.10-2.56, p = 0.02) and major bleeding events (RR, 1.90; 95% CI 1.46-2.48, p < 0.01). Long-term combination therapy failed to reduce the risk of major vascular events (RR, 0.92; 95% CI 0.84-1.03, p = 0.09). Conclusions: Compared with monotherapy, short-term aspirin in combination with clopidogrel is more effective as secondary prevention of stroke or TIA without increasing the risk of hemorrhagic stroke and major bleeding events. Long-term combination therapy does not reduce the risk of stroke recurrence, and is associated with increased major bleeding events. The clinical applicability of the findings of this systematic review, however, needs to be confirmed in future clinical trials.

Keywords:
Stroke, Transient ischemic attack, Antiplatelet therapy, Secondary prevention, Meta-analysis
1.
Mathers CD, Loncar D: Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006;3:e442.
2.
Boysen G, Truelsen T: Prevention of recurrent stroke. Neurol Sci 2000;21:67-72.
3.
Algra A, van Gijn J: Aspirin at any dose above 30 mg offers only modest protection after cerebral ischaemia. J Neurol Neurosurg Psychiatry 1996;60:197-199.
4.
Antithrombotic Trialists' Collaboration: Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002;324:71-86.
5.
Warlow C: Secondary prevention of stroke. Lancet 1992;339:724-727.
6.
Antithrombotic Trialists' Collaboration: Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009;373:1849-1860.
7.
Herbert JM, Dol F, Bernat A, Falotico R, Lale A, Savi P: The antiaggregating and antithrombotic activity of clopidogrel is potentiated by aspirin in several experimental models in the rabbit. Thromb Haemost 1998;80:512-518.
8.
Makkar RR, Eigler NL, Kaul S, Frimerman A, Nakamura M, Shah PK, et al: Effects of clopidogrel, aspirin and combined therapy in a porcine ex vivo model of high-shear induced stent thrombosis. Eur Heart J 1998;19:1538-1546.
9.
Serebruany VL, Malinin AI, Ziai W, Pokov AN, Bhatt DL, Alberts MJ, et al: Effects of clopidogrel and aspirin in combination versus aspirin alone on platelet activation and major receptor expression in patients after recent ischemic stroke: for the Plavix Use for Treatment of Stroke (PLUTO-Stroke) trial. Stroke 2005;36:2289-2292.
10.
Wang Y, Wang Y, Zhao X, Liu L, Wang D, Wang C, et al: Clopidogrel with aspirin in acute minor stroke or transient ischemic attack. N Engl J Med 2013;369:11-19.
11.
Hankey GJ: Dual antiplatelet therapy in acute transient ischemic attack and minor stroke. N Engl J Med 2013;369:82-83.
12.
Diener HC, Bogousslavsky J, Brass LM, Cimminiello C, Csiba L, Kaste M, et al: Aspirin and clopidogrel compared with clopidogrel alone after recent ischaemic stroke or transient ischaemic attack in high-risk patients (MATCH): randomised, double-blind, placebo-controlled trial. Lancet 2004;364:331-337.
13.
Kennedy J, Hill MD, Ryckborst KJ, Eliasziw M, Demchuk AM, Buchan AM; FASTER Investigators: Fast assessment of stroke and transient ischaemic attack to prevent early recurrence (FASTER): a randomised controlled pilot trial. Lancet Neurol 2007;6:961-969.
14.
Hankey GJ, Johnston SC, Easton JD, Hacke W, Mas JL, Brennan D, et al: Effect of clopidogrel plus ASA vs. ASA early after TIA and ischaemic stroke: a substudy of the CHARISMA trial. Int J Stroke 2011;6:3-9.
15.
SPS3 Investigators; Benavente OR, Hart RG, McClure LA, Szychowski JM, Coffey CS, et al: Effects of clopidogrel added to aspirin in patients with recent lacunar stroke. N Engl J Med 2012;367:817-825.
16.
European Stroke Organisation (ESO) Executive Committee; ESO Writing Committee: Guidelines for management of ischaemic stroke and transient ischaemic attack 2008. Cerebrovasc Dis 2008;25:457-507.
17.
Wang YJ, Zhang SM, Zhang L, Wang CX: Chinese guidelines for the secondary prevention of ischemic stroke and transient ischemic attack 2010. CNS Neurosci Ther 2012;18:93-101.
18.
Kern R, Nagayama M, Toyoda K, Steiner T, Hennerici MG, Shinohara Y: Comparison of the European and Japanese guidelines for the management of ischemic stroke. Cerebrovasc Dis 2013;35:402-418.
19.
Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, et al: Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke 2014;45:2160-2236.
20.
Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al: Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin Trials 1996;17:1-12.
21.
Lee M, Saver JL, Hong KS, Rao NM, Wu YL, Ovbiagele B: Risk-benefit profile of long-term dual-versus single-antiplatelet therapy among patients with ischemic stroke: a systematic review and meta-analysis. Ann Intern Med 2013;159:463-470.
22.
Bal Dit Sollier C, Crassard I, Simoneau G, Bergmann JF, Bousser MG, Drouet L: Effect of the thromboxane prostaglandin receptor antagonist terutroban on arterial thrombogenesis after repeated administration in patients treated for the prevention of ischemic stroke. Cerebrovasc Dis 2009;28:505-513.
23.
Markus HS, Droste DW, Kaps M, Larrue V, Lees KR, Siebler M, et al: Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial. Circulation 2005;111:2233-2240.
24.
Wong KS, Chen C, Fu J, Chang HM, Suwanwela NC, Huang YN, et al: Clopidogrel plus aspirin versus aspirin alone for reducing embolisation in patients with acute symptomatic cerebral or carotid artery stenosis (CLAIR study): a randomised, open-label, blinded-endpoint trial. Lancet Neurol 2010;9:489-497.
25.
Benavente OR, White CL, Pearce L, Pergola P, Roldan A, Benavente MF, et al: The Secondary Prevention of Small Subcortical Strokes (SPS3) study. Int J Stroke 2011;6:164-175.
26.
Diener HC, Weber R: Clopidogrel added to aspirin adds no benefit but bleeding risk in patients with recent lacunar stroke. Stroke 2013;44:861-863.
27.
Wang Y, Johnston SC; CHANCE Investigators: Rationale and design of a randomized, double-blind trial comparing the effects of a 3-month clopidogrel-aspirin regimen versus aspirin alone for the treatment of high-risk patients with acute nondisabling cerebrovascular event. Am Heart J 2010;160:380-386.e1.
28.
Meyer DM, Albright KC, Allison TA, Grotta JC: LOAD: a pilot study of the safety of loading of aspirin and clopidogrel in acute ischemic stroke and transient ischemic attack. J Stroke Cerebrovasc Dis 2008;17:26-29.
29.
Chimowitz MI, Lynn MJ, Derdeyn CP, Turan TN, Fiorella D, Lane BF, et al: Stenting versus aggressive medical therapy for intracranial arterial stenosis. N Engl J Med 2011;365:993-1003.
30.
King A, Bath PM, Markus HS: Clopidogrel versus dipyridamole in addition to aspirin in reducing embolization detected with ambulatory transcranial Doppler: a randomized trial. Stroke 2011;42:650-655.
31.
Kwon SU, Hong KS, Kang DW, Park JM, Lee JH, Cho YJ, et al: Efficacy and safety of combination antiplatelet therapies in patients with symptomatic intracranial atherosclerotic stenosis. Stroke 2011;42:2883-2890.
32.
Grau AJ, Reiners S, Lichy C, Buggle F, Ruf A: Platelet function under aspirin, clopidogrel, and both after ischemic stroke: a case-crossover study. Stroke 2003;34:849-854.
33.
Helgason CM, Grossi E, Pandey D, Valika A, Cursio J, Brace LD: Platelet aggregation and recruitment with aspirin-clopidogrel therapy. Cerebrovasc Dis 2008;25:392-400.
34.
Payne DA, Jones CI, Hayes PD, Thompson MM, London NJ, Bell PR, et al: Beneficial effects of clopidogrel combined with aspirin in reducing cerebral emboli in patients undergoing carotid endarterectomy. Circulation 2004;109:1476-1481.
35.
Zhao L, Fletcher S, Weaver C, Leonardi-Bee J, May J, Fox S, et al: Effects of aspirin, clopidogrel and dipyridamole administered singly and in combination on platelet and leucocyte function in normal volunteers and patients with prior ischaemic stroke. Thromb Haemost 2005;93:527-534.
36.
Serebruany VL, Malinin AI, Pokov AN, Hanley DF: Antiplatelet profiles of the fixed-dose combination of extended-release dipyridamole and low-dose aspirin compared with clopidogrel with or without aspirin in patients with type 2 diabetes and a history of transient ischemic attack: a randomized, single-blind, 30-day trial. Clin Ther 2008;30:249-259.
37.
Geraghty OC, Paul NL, Chandratheva A, Rothwell PM: Low risk of rebound events after a short course of clopidogrel in acute TIA or minor stroke. Neurology 2010;74:1891-1896.
38.
Sanofi: COMbination of Clopidogrel and Aspirin for Prevention of Early Recurrence in Acute Atherothrombotic Stroke (COMPRESS). ClinicalTrials.gov. http://clinicaltrials.gov/show/NCT00814268 (first received December 23, 2008).
39.
University of California, San Francisco: Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial. ClinicalTrials.gov. http://clinicaltrials.gov/ct2/show/NCT00991029 (first received October 6, 2009).
40.
Bhatt DL, Fox KA, Hacke W, Berger PB, Black HR, Boden WE, et al: Clopidogrel and aspirin versus aspirin alone for the prevention of atherothrombotic events. N Engl J Med 2006;354:1706-1717.
41.
Gaciong Z: [Clopidogrel and aspirin versus aspirin alone in prevention of atherothrombotic events. The results of CHARISMA study]. Kardiol Pol 2006;64:548-551; discussion 551-552.
42.
Palacio S, Hart RG, Pearce LA, Anderson DC, Sharma M, Birnbaum LA, et al: Effect of addition of clopidogrel to aspirin on stroke incidence: meta-analysis of randomized trials. Int J Stroke 2013, DOI: 10.1111/ijs.12050.
43.
Huang Y, Li M, Li JY, Li M, Xia YP, Mao L, et al: The efficacy and adverse reaction of bleeding of clopidogrel plus aspirin as compared to aspirin alone after stroke or TIA: a systematic review. PLoS One 2013;8:e65754.
44.
Geeganage CM, Diener HC, Algra A, Chen C, Topol EJ, Dengler R, et al: Dual or mono antiplatelet therapy for patients with acute ischemic stroke or transient ischemic attack: systematic review and meta-analysis of randomized controlled trials. Stroke 2012;43:1058-1066.
45.
Wong KS, Wang Y, Leng X, Mao C, Tang J, Bath PM, et al: Early dual versus mono antiplatelet therapy for acute non-cardioembolic ischemic stroke or transient ischemic attack: an updated systematic review and meta-analysis. Circulation 2013;128:1656-1666.
46.
Li X, Zhou G, Zhou X, Zhou S: The efficacy and safety of aspirin plus dipyridamole versus aspirin in secondary prevention following TIA or stroke: a meta-analysis of randomized controlled trials. J Neurol Sci 2013;332:92-96.
47.
Martens RJ, Vink H, van Oostenbrugge RJ, Staals J: Sublingual microvascular glycocalyx dimensions in lacunar stroke patients. Cerebrovasc Dis 2013;35:451-454.
48.
Lavallée PC, Labreuche J, Faille D, Huisse MG, Nicaise-Roland P, Dehoux M, et al: Circulating markers of endothelial dysfunction and platelet activation in patients with severe symptomatic cerebral small vessel disease. Cerebrovasc Dis 2013;36:131-138.
© 2014 S. Karger AG, Basel
2014
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.